Fig. 8: High throughput screening of pharmaceuticals using InCell analyser with GlomSpheres.
From: GlomSpheres as a 3D co-culture spheroid model of the kidney glomerulus for rapid drug-screening
a Untreated LP (podocin mutant) GlomSphere. Podocytes (green) are shown to incompletely cover GlomSphere surface. b Untreated LY (wild type) GlomSphere. Podocytes more completely cover GlomSphere surface, increasing its apparent size. c LP (podocin mutant) spheroid treated for 5 days with a podocin-modifying compound (53). Podocyte retention appears to have been improved and the GlomSphere looks similar to the wild type condition. d Quantified GFP mean fluorescence intensity of GlomSpheres treated with several disease modifying compounds. Many of these compounds are sufficient to restore GFP fluorescence (and therefore podocyte retention) to wildtype (LY) levels when compared to untreated GlomSpheres (Un). e Quantified podocyte coverage percentage of GlomSphere following treatment. Once again the assay appears to have demonstrated several compounds capacity to protect podocyte retention, whilst showing that others are ineffective. f 2D podocyte adhesion assay testing the same compounds. Results shown as relative podocyte attachment. It is shown that whilst WT and PM adhesion is significantly different, many compounds appear less effective at rescuing adhesion when tested with this assay. Statistical analyses are Tukey’s multiple comparison. ****refers to P = < 0.0001, ***refers to P = > 0.0001, **refers to P = > 0.001, *refers to P = > 0.01 . (~N = 12 spheroids per condition).
